Investigators analyzed the outcome of HLA-B27 ankylosing spondylitis and HLA-DRB1 rheumatoid arthritis risk alleles on the composition of the intestinal microbiome in healthy individuals.
The Assessment of Spondyloarthritis International Society health index could be used in the future to represent the health status of spondyloarthritis in a systematic way, according to a new study.
Treatment of bio-naive patients with ankylosing spondylitis with golimumab or infliximab for 6 months was associated with reduced healthcare resource utilization and increased work activity and activity.
Researchers evaluated the factors associated with the presence of peripheral manifestations in patients with spondyloarthritis.
Two-thirds of patients with ankylosing spondylitis who achieved clinical remission with infliximab demonstrated symptom flares and clinical relapse soon after treatment withdrawal.
Syndesmophytes occurred less frequently at the thoracolumbar vertebral rim near the aorta in patients with ankylosing spondylitis.
The COAST-X trial was conducted in 305 biologic disease-modifying antirheumatic drug (bDMARD)-naïve patients with nr-axSpA.
Chronic widespread pain may be prevalent in patients with ankylosing spondylitis and undifferentiated spondyloarthritis.
Patient opinion on education, periodic reassessments, and exercise monitoring may be helpful in designing new supervised group exercise programs.
Whole-body MRI may be useful for mapping inflammatory lesions of peripheral joints and entheses in patients with axial spondyloarthritis.